Ray N - Search Results

1

Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: the CASTLE biomarker substudy.

Moyle G, Hardy H, Uy J, Ray N, Jimenez-Exposito MJ, McGrath D, DeJesus E. Moyle G, et al. Among authors: ray n. Antivir Ther. 2014;19(7):693-9. doi: 10.3851/IMP2778. Epub 2014 Apr 16. Antivir Ther. 2014. PMID: 24739445 Clinical Trial.

2

Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002).

Hwang C, Schürmann D, Sobotha C, Boffito M, Sevinsky H, Ray N, Ravindran P, Xiao H, Keicher C, Hüser A, Krystal M, Dicker IB, Grasela D, Lataillade M. Hwang C, et al. Among authors: ray n. Clin Infect Dis. 2017 Aug 1;65(3):442-452. doi: 10.1093/cid/cix239. Clin Infect Dis. 2017. PMID: 28369211 Free PMC article. Clinical Trial.

3

Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.

Nettles RE, Schürmann D, Zhu L, Stonier M, Huang SP, Chang I, Chien C, Krystal M, Wind-Rotolo M, Ray N, Hanna GJ, Bertz R, Grasela D. Nettles RE, et al. Among authors: ray n. J Infect Dis. 2012 Oct 1;206(7):1002-11. doi: 10.1093/infdis/jis432. Epub 2012 Aug 14. J Infect Dis. 2012. PMID: 22896665 Clinical Trial.

4

The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates.

Ray N, Li T, Lin Z, Protack T, van Ham PM, Hwang C, Krystal M, Nijhuis M, Lataillade M, Dicker I. Ray N, et al. J Acquir Immune Defic Syndr. 2017 May 1;75(1):52-60. doi: 10.1097/QAI.0000000000001304. J Acquir Immune Defic Syndr. 2017. PMID: 28234686 Free PMC article.

5

Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study.

Dicker I, Zhang S, Ray N, Beno BR, Regueiro-Ren A, Joshi S, Cockett M, Krystal M, Lataillade M. Dicker I, et al. Among authors: ray n. PLoS One. 2019 Oct 17;14(10):e0224076. doi: 10.1371/journal.pone.0224076. eCollection 2019. PLoS One. 2019. PMID: 31622432 Free PMC article. Clinical Trial.

6

Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.

Ray N, Hwang C, Healy MD, Whitcomb J, Lataillade M, Wind-Rotolo M, Krystal M, Hanna GJ. Ray N, et al. J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):7-15. doi: 10.1097/QAI.0b013e31829726f3. J Acquir Immune Defic Syndr. 2013. PMID: 23614999 Clinical Trial.

7

Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.

Zhou N, Nowicka-Sans B, McAuliffe B, Ray N, Eggers B, Fang H, Fan L, Healy M, Langley DR, Hwang C, Lataillade M, Hanna GJ, Krystal M. Zhou N, et al. Among authors: ray n. J Antimicrob Chemother. 2014 Mar;69(3):573-81. doi: 10.1093/jac/dkt412. Epub 2013 Oct 14. J Antimicrob Chemother. 2014. PMID: 24128669

8

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.

Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, Mason SW, Hwang CK, Grasela DM, Ray N, Cyktor JC, Coffin JM, Acosta EP, Koup RA, Mellors JW, Eron JJ; AIDS Clinical Trials 5326 Study Team. Gay CL, et al. Among authors: ray n. J Infect Dis. 2017 Jun 1;215(11):1725-1733. doi: 10.1093/infdis/jix191. J Infect Dis. 2017. PMID: 28431010 Free PMC article. Clinical Trial.

9

In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068.

Nowicka-Sans B, Gong YF, McAuliffe B, Dicker I, Ho HT, Zhou N, Eggers B, Lin PF, Ray N, Wind-Rotolo M, Zhu L, Majumdar A, Stock D, Lataillade M, Hanna GJ, Matiskella JD, Ueda Y, Wang T, Kadow JF, Meanwell NA, Krystal M. Nowicka-Sans B, et al. Among authors: ray n. Antimicrob Agents Chemother. 2012 Jul;56(7):3498-507. doi: 10.1128/AAC.00426-12. Epub 2012 Apr 30. Antimicrob Agents Chemother. 2012. PMID: 22547625 Free PMC article.

10

Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.

Li Z, Zhou N, Sun Y, Ray N, Lataillade M, Hanna GJ, Krystal M. Li Z, et al. Among authors: ray n. Antimicrob Agents Chemother. 2013 Sep;57(9):4172-80. doi: 10.1128/AAC.00513-13. Epub 2013 Jun 17. Antimicrob Agents Chemother. 2013. PMID: 23774428 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

555 results

Search Page

Filters